openPR Logo
Press release

Hemophilia A FDA Approvals, Clinical Trials, Pipeline Insights, Drugs and Companies | DelveInsight

01-28-2025 07:52 PM CET | Health & Medicine

Press release from: ABNewswire

Hemophilia A FDA Approvals, Clinical Trials, Pipeline

DelveInsight's, "Hemophilia A Pipeline Insight" report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Hemophilia A pipeline landscape. It covers the Hemophilia A pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia A therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Hemophilia A Treatment Landscape. Click here to read more @ Hemophilia A Pipeline Outlook [https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight-2020?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Hemophilia A Pipeline Report

* In January 2025:- CSL Behring:- A Phase 3, Open-label, Multicenter, Pharmacokinetics, Efficacy, and Safety Study of a Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Previously Treated Patients (PTPs) With Hemophilia A. For bridging the available global clinical data of rVIII-SingleChain, with the Chinese population, the aim of this study in China is to investigate the pharmacokinetics (PK) of rVIII-SingleChain after an initial and repeat dose and to assess efficacy and safety during 2 to 3 times weekly prophylaxis treatment with rVIII-SingleChain in male Chinese PTPs with severe hemophilia A (FVIII activity less than [



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hemophilia A FDA Approvals, Clinical Trials, Pipeline Insights, Drugs and Companies | DelveInsight here

News-ID: 3837814 • Views:

More Releases from ABNewswire

Luxe Living Home Essentials Brings Elevated Kitchen Solutions to Busy American Households Nationwide
Luxe Living Home Essentials Brings Elevated Kitchen Solutions to Busy American H …
Luxe Living Home Essentials, a woman-owned lifestyle brand founded by bestselling author Loreitha Lacewell, is transforming everyday cooking with thoughtfully designed kitchen products that balance style, functionality, and affordability. The brand has quickly established itself as a trusted destination for quality home essentials through strategic e-commerce growth and engaging pop-up retail experiences. Luxe Living Home Essentials is redefining the home and kitchen marketplace with a carefully curated collection of products designed
The Future of Commercial Hacking and Demolition in Singapore: 2026 Market Trends
The Future of Commercial Hacking and Demolition in Singapore: 2026 Market Trends
Explore key 2026 trends shaping commercial hacking and demolition in Singapore, including market growth, tech innovations, regulations, and opportunities. Visit us today! Singapore's built environment is constantly being renewed. As commercial properties adapt to new business models, regulatory standards, and sustainability goals, the role of hacking and demolition has become increasingly strategic. What was once viewed as a basic preparatory task is now recognised as a critical phase that determines project
New Year Resolution Meets Social Impact: Maple and Mocha Coffee Extends Holiday Giving Through 2025
New Year Resolution Meets Social Impact: Maple and Mocha Coffee Extends Holiday …
Following successful holiday season launch, Maple and Mocha Coffee continues its commitment to the Kyempapu Water Project into the new year. The company's Vermont Maple Pecan blend bridges the gap between holiday indulgence and New Year wellness goals while maintaining its 10% donation pledge to support clean water access in Kirinda village. The transition from holiday indulgence to New Year wellness traditionally challenges specialty food companies, but Maple and Mocha Coffee
Truthkins Gives Families a New Way to Tackle Childhood Emotions in the New Year with Faith-Based Plush Toys
Truthkins Gives Families a New Way to Tackle Childhood Emotions in the New Year …
As parents set goals for the year ahead, Truthkins offers a hands-on tool for helping children understand and navigate their feelings. Created by Rick Dieterle ("Dee-ter-Lee"), a New Hampshire dad who wanted something better for his own kids, each Truthkins set includes two plush characters representing opposing emotions, a reminder wristband, an illustrated storybook, and a Bible blanket that connects with others to build a collectible mega blanket. The new year

All 5 Releases


More Releases for Hemophilia

Rising Occurrence Of Genetic Abnormalities Fuels Hemophilia Market Growth: Stren …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts What Is the Expected CAGR for the Hemophilia Market Through 2025? In recent times, there has been a significant expansion in the hemophilia market. The market, which stood at $13.83 billion in 2024, is projected to inflate to $15.13 billion in 2025, exhibiting a compound annual growth rate (CAGR)
Global Hemophilia Market Size & Trends
According to a new market research report published by Global Market Estimates, the global hemophilia market is projected to grow at a CAGR of 6.8% from 2023 to 2028. During the forecast period, the global hemophilia market is anticipated to experience growth due to advancements in medical research, an increase in hemophilia incidence, and rising awareness and diagnosis. Browse 147 Market Data Tables and 115 Figures spread through 163 Pages and
Acquired Hemophilia Treatment Market - Embracing Hope, Defying Hemophilia: Trans …
Newark, New Castle, USA: The "Acquired Hemophilia Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Acquired Hemophilia Treatment Market: https://www.growthplusreports.com/report/acquired-hemophilia-treatment-market/7748 This latest report researches the industry structure,
Hemophilia Market
Hemophilia is an inherited genetic syndrome which impairs body-2019s capability to control blood clotting or coagulation. The episodes of bleeding mainly depend on the severity of hemophilia issue. There are two major kinds of hemophilia namely Hemophilia A & Hemophilia B. Hemophilia A is considered to be five times more prevailing as compared to hemophilia B. Occurrence of hemophilia A is found in one out of five or six thousand
Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Koval …
ReportsWorldwide has announced the addition of a new report title Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Kovaltry, Feiba), By Type of Hemophilia (Hemophilia A, Hemophilia B), By Treatment (On-Demand, Prophylaxis), By Therapy (Replacement , Immune Tolerance Induction ) Outlook 2022 to its growing collection of premium market research reports. Hemophilia is an inherited bleeding disorder that slows the blood clotting process. The people suffering from this condition experience prolonged
In-depth analysis of the Global Hemophilia Market: hemophilia A, hemophilia B, h …
Latest industry research report on: Global Hemophilia Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts Request For Sample Report @ http://www.marketresearchreports.biz/sample/sample/1064504 The hemophilia market has entered into an era of unprecedented growth rate with a variety of treatment options. Development of new therapeutics along with expansion in the current treatment options has presented new opportunities to the market. Hemophilia being an inherited genetic bleeding disorder causes